1	Who is most at risk of dying if infected with SARS-CoV-2? A mortality risk factor analysis
2	using machine learning of COVID-19 patients over time in a large Mexican population.
3	Lauren D. Liao, ^{1*} Alan E. Hubbard, ¹ Juan Pablo Gutiérrez, ² Arturo Juárez-Flores, ² Kendall
4	Kikkawa, ³ Ronit Gupta, ¹ Yana Yarmolich, ¹ Iván de Jesús Ascencio-Montiel, ⁴ Stefano M.
5	Bertozzi ^{1,5,6}
6	Affiliations:
7	¹ University of California, Berkeley, School of Public Health, Berkeley, CA, USA
8	² Center for Policy, Population & Health Research, School of Medicine, Universidad
9	Nacional Autónoma de México, Mexico City, Mexico
10	³ Micron Technology, Boise, ID, USA
11	⁴ Instituto Mexicano del Seguro Social, CDMX, México
12	⁵ University of Washington School of Public Health, Seattle, WA, USA
13	⁶ Instituto Nacional de Salud Pública, Cuernavaca, MOR, México
14	*Correspondence to: ldliao@berkeley.edu (LDL)
15	Word count: 2884/3000
 16 17 18 19 20 21 22 23 24 25 26 27 28 	

29 Key messages

30 What is already known on this topic

- 31 Studies for Mexico and other countries have suggested that pre-existing conditions such as renal
- 32 disease, diabetes, hypertension, and obesity are strongly associated with COVID-19 mortality.
- 33 While age and the presence of pre-existing conditions have been shown to predict mortality,
- 34 other studies have typically used less powerful statistical approaches, have had smaller sample
- 35 sizes, and have not been able to describe changes over time.

36 What this study adds

37 This study examines mortality risk in a very large population (> 60 M); it uses powerful

38 ensemble machine learning methods that outperform regression analyses; and it demonstrates

39 marked changes over time in the degree to which different risk factors predict mortality.

40 How this study might affect research, practice or policy

Because we show an important improvement in predictive performance over traditional regression analyses, and the ability to update estimates as the pandemic evolves, we argue that these methods should be much more widely used to inform national programming in Mexico and elsewhere. Programs that assume that predictive models don't change over time as variants emerge and as pre-existing immunity evolves due to vaccination and prior infection will not accurately predict mortality risk.

47

49 Abstract

50 Background: COVID-19 would kill fewer people if health programs can predict who is at 51 higher risk of mortality because resources can be targeted to protect those people from infection. 52 We predict mortality in a very large population in Mexico with machine learning using 53 demographic variables and pre-existing conditions. 54 Methods: We conducted a population-based cohort study with over 1.4 million laboratory-55 confirmed COVID-19 patients using the Mexican social security database. Analysis is performed 56 on data from March 2020 to November 2021 and over three phases: (1) from March to October 57 in 2020, (2) from November 2020 to March 2021, and (3) from April to November 2021. We 58 predict mortality using an ensemble machine learning method, *super learner*, and independently 59 estimate the adjusted mortality relative risk of each pre-existing condition using targeted 60 maximum likelihood estimation. 61 **Results:** Super learner fit has a high predictive performance (C-statistic: 0.907), where age is the 62 most predictive factor for mortality. After adjusting for demographic factors, renal disease, 63 hypertension, diabetes, and obesity are the most impactful pre-existing conditions. Phase analysis 64 shows that the adjusted mortality risk decreased over time while relative risk increased for each 65 pre-existing condition. 66 **Conclusions:** While age is the most important predictor of mortality, younger individuals with 67 hypertension, diabetes and obesity are at comparable mortality risk as individuals who are 20 68 years older without any of the three conditions. Our model can be continuously updated to 69 identify individuals who should most be protected against infection as the pandemic evolves.

70 Keywords: mortality; death; COVID-19; biostatistics; international health

71 Introduction

72	The probability that someone infected with SARS-CoV-2 dies has varied enormously
73	over time, among countries, and among population groups within countries. Interest in
74	understanding who is at a higher risk of death has grown as this heterogeneity became more
75	apparent. Identifying people at higher risk of severe disease and death will help health systems
76	better respond and focus prevention resources on protecting them. We examine Mexico, a
77	country with a very high reported case-fatality rate (4.7%) among those who have laboratory-
78	confirmed coronavirus disease 2019 (COVID-19) as of September 23, 2022 [1].
79	Previous analyses in Mexico have found diabetes, obesity, hypertension,
80	immunosuppression, and renal disease to be significant risk factors along with age and sex.
81	Multiple authors have identified obesity and diabetes as important risk factors for mortality [2–5].
82	Escobedo de-la Peña et al. also found a strong association with hypertension, which is consistent
83	with results from Giannouchos et al. [5,6]. Late-stage chronic kidney disease, although less
84	prevalent, has also consistently been identified as a COVID-19 mortality risk factor . Older/ male
85	patients tend to have higher mortality risks than younger/ female patients [3,5,6]. In a previous
86	analysis, we found interactions between those comorbidities, suggesting a synergic effect when
87	having more than one of diabetes, hypertension, and obesity (larger odds ratio when reporting the
88	3 conditions vs. one or two) [7]. We also found that the odds ratio increased by age group with
89	those over age 80 having 30-fold the risk of those 20 to 29 [7]. One important consideration is
90	that the prevalence of diabetes and hypertension is positively associated with age, so it has not
91	been clear how this interaction is related to mortality risk. A more adaptive analysis performed
92	by Martínez-Martínez et al. developed a prediction model for severity of COVID-19, defined by
93	hospitalization and/or mortality. They examined the relationship of 14 variables with

94 hospitalization and mortality using interaction terms and splines to account for non-linear95 relationships [8].

96 The pattern of age, sex, and comorbidities being associated with higher mortality risk is 97 not specific to Mexico, and the global literature on such associations is extensive. Researchers 98 have identified old age, diabetes, obesity, chronic renal failure, and congestive heart failure to be 99 strongly associated with severe infection amongst both sexes in the Spanish population [9]. 100 Researchers in Brazil showed that older age, male, kidney disease, obesity and/ or diabetes are 101 strong predictors of mortality amongst other comorbidities such as chronic liver disease, 102 immunosuppression, and cardiovascular disease [10,11]. Another study used United Kingdom 103 Biobank data and showed that pre-existing dementia, diabetes, chronic obstructive pulmonary 104 disease (COPD), pneumonia, and depression were positively associated with risk of 105 hospitalization and death [12]. An analysis from France found age, diabetes, hypertension, 106 obesity, cancer, and kidney and lung transplants to be associated with risk of COVID-19-related 107 hospitalization and mortality, among others [13]. A Canadian study reported dementia, chronic 108 kidney disease, cardiovascular disease, diabetes, COPD, severe mental illness, organ transplant, 109 hypertension, and cancer to be significant predictors of mortality [14]. Our goal in this study is 110 not only to predict mortality using demographic factors and comorbidities, but to show how 111 those predictions change over time in this rapidly evolving pandemic.

Although mortality risk estimation and risk factor identification have been examined in prior studies, we are concerned about the statistical validity and interpretation of the standard methods. A commonly used prediction tool, logistic regression, assumes a linear relationship of predictors against the log odds of mortality risk, but this logit-linear assumption will lead inevitably to biased estimates of risk (either under- or over-predict the risk) for subsets of the

population. We instead used flexible, data-adaptive methods that can capture non-linearities in the dose-response, such as potential nonlinear interactions between the predictors (e.g., the potential interaction of age and diabetes on predicting death) [15,16]. The better the model fits the study population; the more likely estimates are closer to the true joint relationship of mortality and risk factors.

122 We included pre-existing conditions, demographic variables, the Mexican state where the 123 patient was treated, and the month that the patient initiated care to fit our prediction algorithm. 124 We conducted the analysis using an ensemble machine learning algorithm, super learner, to form 125 optimal combination of predictions from multiple machine learning methods [15,16]. We also 126 estimated the comparative importance of variables for mortality risk prediction (holding all other 127 variables constant) by nonparametrically estimating quantities inspired by causal parameters 128 (parameters that compare so-called counterfactual distributions, in our case, causal relative risks). 129 The statistical goal is to estimate and provide robust inference for impact estimates of the 130 predictors without the arbitrary modeling assumptions that characterize the great majority of 131 prior work [17].

132 Methods

133 Study population and design

The study population is drawn from the Mexican Social Security Institute (IMSS), a vertically integrated insurance and health system that provides coverage for over 60 million private sector employees and their families, including their parents, children and spouse. IMSS also provided care as part of the COVID-19 response for some non-beneficiaries, who are also included in the dataset.

139 The data were recorded from March 1st, 2020, to November 3rd, 2021 in a platform 140 called SINOLAVE. They reflect the entire population of 4,482,292 patients who were registered 141 as receiving care for suspected COVID-19 at an IMSS facility. The dataset and the data entry 142 process have been described previously [18]. The demographic variables include age, sex, 143 insured by IMSS, and indigenous status. The data contains pre-existing conditions reported by 144 the patient or the family at presentation: asthma, cardiovascular disease, chronic liver disease, 145 chronic obstructive pulmonary disease, diabetes, hemolytic anemia, human immunodeficiency 146 virus, hypertension, immunosuppression, neurological disease, obesity, cancer, renal disease and 147 tuberculosis, as well as whether the patient currently smokes. Patients were asked at presentation 148 about their pre-existing health conditions; these were not ascertained with reference to the 149 patient's medical record, even for those patients insured by the IMSS. The data also includes the 150 Mexican state in which the patient received care, COVID-19 test results (from both polymerase 151 chain reaction (PCR) tests and antigen tests), the month that the patient initiated care, and 152 mortality. In addition, we extracted a different dataset from the National Council of Science and 153 Technology to determine the dominant circulating variant in each month [19]. A short summary 154 can be found in **Table 1** (Supplemental Table S1). We define COVID-19 positive as a positive 155 PCR or antigen test.

From the full data set, we generated an analytic sample (n = 1,423,720) (**Supplemental Figure S1**). We exclude those under the age of 20 years, those without any positive COVID-19 test result from either the PCR or antigen tests, and those with unknown pre-existing conditions. We also create a phase variable that corresponds to changes in the epidemic curve into three: phase 1 is from March 1st, 2020, to October 31st, 2020, phase 2 is from November 1st, 2020, to

March 31st, 2021, and phase 3 is from April 1st, 2021, to November 3rd, 2021 as previouslydescribed [18].

163 Statistical analysis

164 Mortality risk prediction using super learner (SL)

165 We predict mortality risks with SL [15,16], using predictors: pre-existing conditions, 166 demographic variables, the Mexican state where the patient was treated, and the month that the 167 patient initiated care. SL combines a set of user-supplied machine learning algorithms, which 168 includes both simple, parametric fits and flexible algorithms, to create an optimally-weighted 169 combination. This optimal fit is found by creating a combination of algorithms that minimize the 170 cross-validated risk (in our case, the negative log-likelihood). SL has the property that 171 asymptotically it will perform at least as well as the best fitting algorithm in the library [15,16]. 172 Thus, it is important to include a diverse and large set of learners as candidates to ensure the 173 model can fit complex patterns if warranted, but also, simpler, parametric models if simpler fits 174 are sufficient. The following learners were included in the SL library: Bayesian additive regression trees [21], Bayesian generalized linear model [22], elastic net regression [23], 175 176 empirical mean, generalized additive model [24], least absolute shrinkage and selection operator 177 regression [25], logistic regression, multivariate adaptive regression splines [26], random forest 178 [27], ridge regression [28], and extreme gradient boosting algorithms [29]. We estimate the 179 prediction performance, via the AUC, and derive a 95% confidence interval for the estimated 180 AUC [30]. We compare the SL fit using all predictors listed above to a logistic regression with 181 only age entered as a linear term. We compute the AUC for the resulting SL/logistic regression 182 fits with 3-fold cross validation on the 80%, both on the same data used to estimate SL/logistic

regression models (training AUC), as well as a more realistic assessment by using the test set –
the left-out 20% of the available data (testing AUC).

185 To interpret the final prediction model generated by the SL fit, we use the permutation-186 based variable importance measure to identify variables that influence the SL model's prediction 187 [27]. This is performed by permuting the predictor variables one at a time (keeping the other 188 variables fixed) and measuring the magnitude of the decline on the predictive performance (as 189 measured by the change in the average negative log-likelihood). This provides a list of variables 190 ranked by the relative importance to prediction fit but does not provide information on the 191 variable impact on mortality, which led us to another measure of relative risk (RR) using targeted 192 maximum likelihood estimation (TMLE).

193 Pre-existing condition relative risk estimate through targeted maximum likelihood 194 estimation

195 For pre-existing conditions, we estimated a different variable importance measure that is 196 not focused on prediction accuracy but on estimating potential impacts of pre-existing conditions 197 on mortality risk. The impact is estimated by the RR of adjusted means (adjusted for baseline 198 confounders) for the population if everyone had the specific pre-existing condition of interest 199 (the numerator) versus the same population where no one has the specific pre-existing condition 200 (the denominator). To estimate RRs, we used cross-validated targeted minimum-loss-based 201 estimation (cross-validated TMLE). TMLE is a semiparametric, substitution estimator that has 202 shown to be asymptotically efficient (unlike the inverse probability of treatment-weighting 203 estimators [31]). It also has some robustness advantages over other semiparametric efficient 204 approaches, such as augmented inverse probability weighting. TMLE estimates parameters that,

under certain assumptions, can be interpreted as potential causal impacts of these factors on
mortality, in our case, in the form of a causal relative risk. Our ensemble machine learning is
optimized for prediction, but it does not directly provide measures of individual variable
importance. We conducted follow-up procedure (TMLE) to generate interpretable estimates of
variable impact with robust standard errors [32, 33].

210 **Results**

Descriptive results show the age distribution of laboratory-confirmed patients across the three different epidemic phases (**Supplemental Figure S2**). Phases 1 and 2 have similar distributions, and there are more young people (under 30) in phase 3. The six most prevalent preexisting conditions are hypertension, obesity, diabetes, smoking, asthma, and renal disease (**Supplemental Figure S3**). The prevalence of all pre-existing conditions decreased over the three phases, and prevalence of hypertension, obesity, and diabetes were drastically reduced in phase 3.

218 Super learner (SL) prediction

219 SL fit has high prediction accuracy on the testing set (AUC: 0.907 (95% CI: (0.905-220 0.908)). SL leverages XGBoost models (Supplemental Table S2) and significantly outperforms 221 the simple logistic regression model (testing AUC: 0.874 (95% CI: (0.872-0.876)) (Table 2). 222 The logistic regression model overpredicts mortality risks for those roughly above age 75 223 compared to the SL prediction (**Fig. 1**). Permuted variable importance shows, while holding 224 other variables constant, age is consistently the most important for SL prediction in average 225 mortality risk (Supplemental Figure S4 and Table S3). Having multiple comorbidities can 226 dramatically increase risk for those individuals (Fig. 2).

227 Relative risks of pre-existing conditions

- 228 To assess the impact of each pre-existing condition, we estimate their respective relative 229 risks (RRs) of mortality, adjusting for demographic variables. We report the estimated RRs in 230 Table 3, ordered by impact (most to least) (Supplemental Figure S5). The RRs compare the 231 expected risk if all patients have the pre-existing condition (with) versus if all patients do not 232 have the condition (without). The highest impact pre-existing condition is renal disease (RR: 233 3.783, 95% CI: (3.705, 3.862)); diabetes, obesity, and hypertension also have high impact 234 individually (RR: 1.432-1.847). Minimal differences between the risk estimates are shown for 235 smoking and asthma (RR: 1.049 and 1.037, respectively). 236 The phase analyses indicate pre-existing conditions are especially important in phase 3. 237 Phase 1 and 2 are very similar in terms of both risk prediction and adjusted mortality risk
- estimates. However, in phase 3, age is less important in prediction (Supplemental Table S3) and
 RRs drastically increase for every comorbidity. The adjusted risks show the decrease for each
 pre-existing condition in phase 3 (Supplemental Table S4).

241 **Discussion**

Our analysis of (>1.4 million) laboratory-confirmed COVID-19 patients demonstrates that age is by far the most important predictor of average mortality. For those patients with renal disease, diabetes, hypertension, or obesity, having the comorbidity further increases their risk of mortality. A patient with diabetes, hypertension, and obesity is roughly comparable to a patient 20 years older with none of the conditions, based on the predicted mortality (**Fig. 2**). Thus, having a comorbidity increases risk of mortality and should be considered at any age. The reason that comorbidities add little to the predictive power at younger ages is that hypertension and

diabetes are age-related and the reported onset is often for those over 30, so the pre-existingconditions are far less prevalent.

251 Our prediction results using machine learning methods predict better than previous 252 studies, and we demonstrated the feasibility and robustness of using machine learning methods 253 targeted for prediction and variable impact. SL model prediction has an AUC of 0.907, which is 254 higher than any previous Mexican study (AUCs from 0.634 to 0.824) [8,34]. Although age has 255 been well reported by previous studies as important [5,34,35], our analysis is more robust 256 because we do not assume a pre-specified functional relationship between the explanatory 257 variables and the predicted variable, and thereby avoid any arbitrary groupings into age 258 categories. Moreover, since those above age 60 have a higher prevalence of comorbidities, 259 relying on simple logistic regression models can greatly overpredict the average mortality risk 260 for the elder patients. Our study applies TMLE to estimate the adjusted mortality risk ratios for 261 each comorbidity to provide more robust impact estimates that respect time ordering and account 262 for background variables.

263 We find consistent results of comorbidities compared to previous studies, and present 264 phase analyses highlighting the changes in relative risks over time. Previous results from logistic 265 regressions indicated odds ratios of 1.458-2.48 for renal disease, 1.237-1.74 for diabetes, 1.173-266 1.47 for obesity, 1.194-1.315 for hypertension, 0.852-1.02 for smoking, and 0.74-1.420 for 267 asthma [34–36]. Although our analysis is generally consistent with previous findings, our RR 268 estimations have less uncertainty. Renal disease has the greatest impact on mortality, followed 269 by diabetes, hypertension, and obesity; smoking and asthma have negligible impact on mortality 270 risk.

271 This phase-specific analysis produced a seemingly paradoxical finding. The impact of 272 comorbidities on predicted mortality decreased with time (primarily between the second and 273 third wave), but the RR on mortality dramatically increased for the same conditions 274 (Supplemental Table S4 and Figure S5). The apparent explanation is that mortality risk for 275 people without the comorbidities fell faster than for people with them, increasing the relative risk. 276 The decrease in mortality risk is multifactorial and includes a decrease in susceptibility over time 277 (due to prior infection and vaccination), improved treatment, enhanced healthcare response and 278 opportunity to be admitted to a hospital or ICU, and less virulent viral subtypes. This implies that 279 as herd immunity increases, medical resources should focus even more on protecting vulnerable 280 people at older age and those with comorbidities since they are even more likely to experience 281 severe outcomes compared to those who are younger and/or healthier.

282 Readers should be cautious about extrapolating our findings to other populations. 283 Although our sample is large and includes patients from all parts of Mexico, most of the patients 284 were IMSS beneficiaries. In order to access IMSS health services, patients require: a) be a 285 formal-sector worker or retired, b) be a direct dependent of such an employee, c) be a bachelor or 286 postgraduate student in a public institution, d) voluntarily enroll by paying a fee. Thus, the IMSS 287 population skews toward the upper half of the income distribution. Populations without similar 288 access to health services may have different results. It is also important to consider the potential 289 impact of data quality. Pre-existing conditions were self-reported and likely also inconsistently 290 recorded, perhaps in systematic ways that could have biased the results. For example, if people 291 with severe diabetes were more likely to report diabetes as a pre-existing condition, we may 292 overestimate the impact of diabetes on mortality.

293	It is also important to consider what predictive variables are included in this model. We
294	sought to predict risk for an individual in the population using their characteristics prior to
295	infection. In other words, what is this person's risk of death from COVID-19 if they were to be
296	infected? The answer to this question best informs the question of who should be prioritized for
297	protection against infection or for early therapeutic interventions following infection. It does not
298	attempt to predict the likely mortality of a patient who presents to the health services with
299	COVID-19 because information about that patient's severity of their COVID-19-related
300	symptoms will represent important additional predictors of their mortality risk.

301 Abbreviations

- 302 AUC, area under the receiver operating characteristic curve; CI, confidence interval; COPD,
- 303 chronic obstructive pulmonary disease; COVID-19, coronavirus disease of 2019; IMSS, Mexican
- 304 Social Security Institute; PCR, polymerase chain reaction; RR, relative risk; SL, super learner;
- 305 TMLE, targeted maximum likelihood estimation; XGBoost, extreme gradient boosting

306

307 **Declarations:**

308 Acknowledgements

309 We thank the staff of C3.ai DTI for their technical support and our colleagues at University of

310 California, Berkeley, the Mexican National Autonomous University, and the Mexican Social

311 Security Institute (IMSS) for all of the administrative and technical support that has allowed this

312 collaboration to flourish.

313 Authors' contributions

LDL and AEH contributed to the study design and methodology. AJ, YY, and IA contributed to

315 data acquisition. LDL, YY, and KK contributed to data cleaning. LDL led the data analysis and

316 visualization. LDL, AEH, JPG, and SMB interpreted the results. LDL drafted the manuscript

- 317 with support from RG on literature search. AEH and SMB significantly contributed to the
- 318 revision of the manuscript. All authors participated in review and edited the manuscript; all
- 319 authors have read and approved the final manuscript. All authors had full access to all the data in
- 320 the study and accepted responsibility to submit for publication. All authors take responsibility for
- 321 the integrity of the data and the accuracy of the data analysis.

322 Funding

- 323 This research effort was funded by the C3.ai Digital Transformation Institute. The C3.ai DTI was
- 324 established by C3.ai, Microsoft, the University of California, Berkeley (UC Berkeley), the
- 325 University of Illinois at Urbana-Champaign (UIUC), Carnegie Mellon University, University of
- 326 Chicago, MIT, and Princeton University. It is being funded in cash and in kind by C3.ai,
- 327 Microsoft Azure, and the Lawrence Berkeley National Laboratory. The funders had no role in
- 328 access to data, design of the research, or analyses conducted. They have not seen or contributed
- to the manuscript in any way.
- 330 In addition, LDL received funding from the National Science Foundation (DGE 2146752). AEH
- received funding from a global development grant (OPP1165144) from the Bill & Melinda Gates
- 332 Foundation to the University of California, Berkeley, CA, USA.

333 Availability of data and materials

- The study was conducted using confidential patient records subject to strict access controls and
- 335 we are therefore unable to share the data that were used for this study.

336 Ethics approval and consent to participate

- 337 This data-only study was approved on November 4th, 2020, by the Scientific Research National
- 338 Committee (Social Security Mexican Institute) with R-2020-785-165. The University of
- 339 California, Berkeley Institutional Review Board (IRB) determined that the project was exempt
- from IRB approval.

341 **Consent for publication**

342 Not applicable.

343 **Competing interests**

344 All authors declare no competing interests.

345 References
 Hopkins. University of Medicine. Coronavirus Resource Center. <i>Data Stream</i> 2020.
 348 2. Singer M. Deadly Companions: COVID-19 and Diabetes in Mexico. <i>Med Anthropol</i> 349 2020;39:660–5.
 3. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, <i>et al.</i> Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. <i>J Clin Endocrinol Metab</i> 2020;105. doi:10.1210/clinem/dgaa346
 4. Noyola DE, Hermosillo-Arredondo N, Ramírez-Juárez C, <i>et al.</i> Association between obesity and diabetes prevalence and COVID-19 mortality in Mexico: an ecological study. <i>J</i> <i>Infect Dev Ctries</i> 2021;15:1396–403.
 5. Giannouchos TV, Sussman RA, Mier Odriozola JM, <i>et al.</i> Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory– confirmed COVID-19 cases. bioRxiv. 2020. doi:10.1101/2020.06.04.20122481
 Beña JE la, Rascón-Pacheco RA, Ascencio-Montiel I de J, <i>et al.</i> Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico. <i>Arch Med Res</i> 2021;52:443–9.
 Gutierrez JP, Bertozzi SM. Non-communicable diseases and inequalities increase risk of death among COVID-19 patients in Mexico. <i>PLoS One</i> 2020;15:e0240394.
 8. Martínez-Martínez MU, Alpízar-Rodríguez D, Flores-Ramírez R, <i>et al.</i> An Analysis COVID-19 in Mexico: a Prediction of Severity. <i>J Gen Intern Med</i> 2022;37:624–31.
 Gimeno-Miguel A, Bliek-Bueno K, Poblador-Plou B, <i>et al.</i> Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study. <i>PLoS One</i> 2021;16:e0259822.
 369 10. Soares R de CM, Mattos LR, Raposo LM. Risk Factors for Hospitalization and Mortality 370 due to COVID-19 in Espírito Santo State, Brazil. <i>Am J Trop Med Hyg</i> 2020;103:1184–90.
 Wollenstein-Betech S, Silva AAB, Fleck JL, <i>et al.</i> Physiological and socioeconomic characteristics predict COVID-19 mortality and resource utilization in Brazil. <i>PLoS One</i> 2020;15:e0240346.
 Atkins JL, Masoli JAH, Delgado J, <i>et al.</i> Preexisting Comorbidities Predicting COVID- and Mortality in the UK Biobank Community Cohort. <i>J Gerontol A Biol Sci Med Sci</i> 2020;75:2224–30.
 377 13. Semenzato, Botton, Drouin, <i>et al.</i> Chronic diseases, health conditions and risk of 378 COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic 379 in France: a <i>The Lancet Regional</i> 380 https://www.sciencedirect.com/science/article/pii/\$2666776221001356
18

381 14. Ge E, Li Y, Wu S, *et al.* Association of pre-existing comorbidities with mortality and
382 disease severity among 167,500 individuals with COVID-19 in Canada: A population-based
383 cohort study. *PLoS One* 2021;16:e0258154.

van der Laan MJ, Polley EC, Hubbard AE. Super learner. *Stat Appl Genet Mol Biol*2007;6:Article25.

Bernom 16. Polley EC, van der Laan MJ. Super Learner In Prediction. Published Online First:
2010.https://biostats.bepress.com/ucbbiostat/paper266/?TB_iframe=true&width=370.8&height=
658.8 (accessed 26 Jul 2022).

- 17. Petersen ML, van der Laan MJ. Causal models and learning from data: integrating causal
 modeling and statistical estimation. *Epidemiology* 2014;25:418–26.
- 391 18. Juárez-Flores A, Ascencio-Montiel IJ, Gutiérrez JP, et al. COVID-19 in the Mexican
- 392 Social Security Institute (IMSS) population. Prevalent symptoms. bioRxiv. 2022.
- 393 doi:10.1101/2022.04.12.22273734

Vigilancia de variantes del virus SARS-CoV-2. Vigilancia de variantes del virus SARS CoV-2. https://salud.conacyt.mx/coronavirus/variantes/. (accessed 29 Jul 2022).

- 396 20. Hubbard AE, Kennedy CJ, van der Laan MJ. Data-Adaptive Target Parameters. In: van
- der Laan MJ, Rose S, eds. *Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies.* Cham: : Springer International Publishing 2018. 125–42.

Chipman HA, George EI, McCulloch RE. BART: Bayesian additive regression trees.
 aoas 2010;4:266–98.

- 401 22. Dey DK, Ghosh SK, Mallick BK. *Generalized linear models: A Bayesian perspective*.
 402 CRC Press 2000.
- 403 23. Hans C. Elastic Net Regression Modeling With the Orthant Normal Prior. J Am Stat
 404 Assoc 2011;106:1383–93.
- 405 24. Liu. Generalized additive model. *Rep Univ Jyvaskyla Dep Math Stat* Published Online
 406 First: 2008.http://people.vcu.edu/~dbandyop/BIOS625/GAM.pdf
- 407 25. Tibshirani R. Regression Shrinkage and Selection via the Lasso. *J R Stat Soc Series B*408 *Stat Methodol* 1996;**58**:267–88.
- 409 26. Friedman JH. Multivariate Adaptive Regression Splines. *aos* 1991;19:1–67.
- 410 27. Breiman L. Random Forests. *Mach Learn* 2001;45:5–32.
- 411 28. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal
 412 Problems. *Technometrics* 1970;12:55–67.

413

29.

Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. In: Proceedings of the

22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. New York, NY, USA: : Association for Computing Machinery 2016. 785–94.
30. LeDell E, Petersen M, van der Laan M. Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates. <i>Electron J Stat</i> 2015; 9 :1583–607.
31. Rosenbaum PR. Model-Based Direct Adjustment. J Am Stat Assoc 1987;82:387–94.
32. van der Laan MJ, Rubin D. Targeted Maximum Likelihood Learning. <i>Int J Biostat</i> 2006; 2 . doi:10.2202/1557-4679.1043
33. Porter KE, Gruber S, van der Laan MJ, <i>et al.</i> The relative performance of targeted maximum likelihood estimators. <i>Int J Biostat</i> 2011; 7 . doi:10.2202/1557-4679.1308
34. Wollenstein-Betech S, Cassandras CG, Paschalidis IC. Personalized predictive models for symptomatic COVID-19 patients using basic preconditions: Hospitalizations, mortality, and the need for an ICU or ventilator. <i>Int J Med Inform</i> 2020; 142 :104258.
35. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. <i>Ann Epidemiol</i> 2020; 52 :93–8.e2.
36. Hernández-Galdamez DR, González-Block MÁ, Romo-Dueñas DK, <i>et al.</i> Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico. <i>Arch Med Res</i> 2020; 51 :683–9.

	All time (2020/03- 2021/11)	Phase 1 (2020/03- 2020/10)	Phase 2 (2020/11- 2021/03)	Phase 3 (2021/04- 2021/11)
Sample size	1,423,720	303,278	425,698	694,744
Demographic variables				
Age in years (mean (SD))	42.15 (15.70)	46.41 (16.04)	44.89 (16.27)	38.61 (14.34)
Sex = male (%)	729,782 (51.3)	158,248 (52.2)	218,165 (51.2)	353,369 (50.9)
Insured by IMSS = yes (%)	1,358,440 (95.4)	288,588 (95.2)	402,754 (94.6)	667,098 (96.0)
Indigenous = yes (%)	7,381 (0.5)	2,200 (0.7)	1,628 (0.4)	3,553 (0.5)
Pre-existing conditions				
Hypertension = yes (%)	228,901 (16.1)	72,615 (23.9)	83,735 (19.7)	72,551 (10.4)
Diabetes = yes (%)	169,869 (11.9)	55,551 (18.3)	61,120 (14.4)	53,198 (7.7)
Obesity = yes (%)	181,736 (12.8)	55,965 (18.5)	60,217 (14.1)	65,554 (9.4)
Smoking = yes (%)	87,161 (6.1)	21,253 (7.0)	28,346 (6.7)	37,562 (5.4)
Asthma = yes (%)	25,297 (1.8)	7,951 (2.6)	7,765 (1.8)	9,581 (1.4)
Renal Disease Diagnosis = yes (%)	24,099 (1.7)	8,912 (2.9)	8,555 (2.0)	6,632 (1.0)
Outcome				
Death = yes (%)	149,805 (10.5)	53,530 (17.7)	62,517 (14.7)	33,758 (4.9)

Table 1. Summary table of baseline variables and pre-existing conditions

IMSS: Mexican Institute of Social Security; SD: standard deviation

Table 2. Prediction results

	All time	Phase 1	Phase 2	Phase 3
	(2020/03-	(2020/03-	(2020/11-	(2021/04-
	2021/11)	2020/10)	2021/03)	2021/11)
	AUC (95% CI)	AUC (95%CI)	AUC (95%CI)	AUC (95%CI)
Super learner fit	Training: 0.916	Training: 0.887	Training: 0.904	Training: 0.914
	(0.915-0.917)	(0.885-0.888)	(0.903-0.906)	(0.913-0.916)
	Testing: 0.907	Testing: 0.873	Testing: 0.895	Testing: 0.906
	(0.905-0.908)	(0.870-0.876)	(0.892-0.897)	(0.902-0.909)
Age only logistic regression fit	Training: 0.874	Training: 0.845	Training: 0.868	Training: 0.867
	(0.873-0.875)	(0.843-0.846)	(0.866-0.870)	(0.865-0.869)
	Testing: 0.874	Testing: 0.846	Testing: 0.871	Testing: 0.871
	(0.872-0.876)	(0.842-0.850)	(0.868-0.874)	(0.866-0.875)

AUC: area under the receiver operating characteristic curve; CI: confidence interval

	All time (2020/03- 2021/11) Relative Risk (95% CI)	Phase 1 (2020/03-2020/10) Relative Risk (95%CI)	Phase 2 (2020/11-2021/03) Relative Risk (95%CI)	Phase 3 (2021/04-2021/11) Relative Risk (95%CI)
Renal	3.783	2.588	2.994	6.638
disease	(3.705, 3.862)	(2.521, 2.657)	(2.910, 3.080)	(6.361, 6.927)
Diabetes	1.847	1.536	1.594	2.508
	(1.820, 1.875)	(1.508, 1.566)	(1.564, 1.625)	(2.423, 2.596)
Hypertension	1.745	1.427	1.500	2.356
	(1.721, 1.770)	(1.402, 1.452)	(1.474, 1.527)	(2.279, 2.436)
Obesity	1.432	1.269	1.259	1.794
	(1.417, 1.447)	(1.249, 1.288)	(1.239, 1.279)	(1.750, 1.840)
Smoking	1.049	1.001	0.992	1.158
	(1.030, 1.068)	(0.975, 1.028)	(0.966, 1.018)	(1.107, 1.210)
Asthma	1.037	0.941	0.942	1.223
	(1.002, 1.073)	(0.895, 0.989)	(0.892, 0.995)	(1.134, 1.319)

Table 3. Targeted maximum likelihood estimation relative risk results for each pre-existing condition

CI: confidence interval

Fig. 1. Mortality risk prediction comparing age only logistic regression and super learner

GAM: generalized additive model

The smoothed true mortality risk curve is generated using a GAM with integrated smoothness estimation fitted with cubic splines.

Fig. 2. Super learner predicted mortality risk averaged by specific age in two subgroups: those having all obesity, diabetes, and hypertension pre-existing conditions versus those without

Supplemental Material

SupplementalMaterial.pdf:

- Table S1. TableS1 [Complete table of baseline variables and pre-existing conditions]
- Table S2. TableS2 [Weighted combination of the super learner fit]
- Table S3. TableS3 [Top 5 ranked most important variables for prediction]
- Table S4. TableS4 [Targeted maximum likelihood estimation adjusted mortality risk, with or

without the pre-existing condition]

- Figure S1. FigS1 [Flowchart for analytic sample development]
- Figure S2. FigS2 [Age distribution for laboratory-confirmed COVID-19 patients]
- Figure S3. FigS3 [Prevalence of pre-existing conditions prevalence over time]
- Figure S4. FigS4 [Prediction variable importance predicted using the super learner fit]
- Figure S5. FigS5 [Relative risk for each pre-existing condition associated with mortality]



Age-specific mortality risk

Mortality risk comparison between those with versus without multiple pre-existing conditions

